The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Gliclazide Tablets (80mg). Gliclazide Tablet is mainly used in adult patients with type 2 diabetes when dietary control, exercise, and weight loss are not enough to control blood sugar level.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +0.21% | +1.92% | -3.24% |
Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.81B | |
+26.47% | 664B | |
+28.22% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.62% | 234B | |
+4.93% | 199B | |
-10.14% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Receives Approval for Gliclazide Tablet